Posted by Richard Willett - Memes and headline comments by David Icke Posted on 19 April 2024

Personalised medicine will make drug experimentation on populations the norm

In June 2023, the UK’s Medicines and Healthcare products Regulatory Agency (“MHRA”) announced it will be the first drug safety regulator in the world to pilot its own genetic “biobank,” to better understand how a patient’s genetic makeup can impact the safety of their medicines.

“The Yellow Card biobank, which will contain genetic data and patient samples … forms part of a long-term vision for more personalised medicine approaches … [to] enable doctors to target prescriptions using rapid screening tests, so patients … receive the safest medication for them, based on their genetic makeup,” a press release said.

In February 2024, as a personalised medicine project, the MHRA began recruiting patients who have experienced excessive bleeding after taking blood thinners to establish whether they have any special genetic traits which predispose them to excessive bleeding.

It may sound exciting however, personalised genetic medicine is a step towards an era where drug use and experimentation on populations become the norm.

As Dr. Guy Hatchard notes, whilst most pharmaceutical drugs entail adverse reactions and unanticipated side effects, drugs that are tailored to genetic characteristics may potentially have even more serious consequences and long-term adverse outcomes. This is because genetic systems are involved in all the functions of the physiology, its organs, bio-molecular messaging and overall immunity.

The Hollow Heart of Personalised Genetic Medicine

By Dr. Guy Hatchard

A recent article entitled ‘Using ChatGPT to predict the future of personalised medicine’ in the prestigious journal Nature offers the following outlook:

At the centre of the personalised medicine hype is a research field known as pharmacogenomics which aims to study the genetic makeup of people in order to optimise drug prescriptions. It is envisioned that future treatments will be algorithm-based instead of evidence-based that will consider a patient’s genetic, transcriptomic, proteomic, epigenetic and lifestyle factors resulting in individualised medication.

That is a big mouthful; what does it mean? Supposedly, artificial intelligence (“AI”) tools will analyse the results of various genetic tests, microbiology assays and patient questionnaires and then prescribe what drugs will suit an individual best. The falling cost of genetic testing will, according to enthusiastic advocates, enable this process to become the universal healthcare of the near future.

The article finishes with the caveat: personalised medicine still has several limitations that need to be solvedThat is an understatement of gigantic proportions. To understand these limitations, we need to examine how or more correctly if people in medicine are currently using genetic tools to personalise drug prescriptions. In other words, what is really going on here?

A Project to Implement Personalised Medicine

The UK Medicines and Healthcare Products Regulatory Agency (“MHRA”) is currently undertaking an investigation into blood thinners known as direct oral anticoagulants (“DOACs”). According to the MHRA, these drugs, which include rivaroxaban, dabigatran, apixaban and edoxaban, have been found to cause serious bleeding in between 2 to 5% of patients. In some cases, this leads to hospitalisation and even death. 1.5 million patients take DOACs in the UK alone.

The MHRA has started genetic testing of patients affected with DOAC bleeding to discover whether they have any special genetic characteristics which predispose them to excessive bleeding. According to Dr. Alison Cave, the MHRA chief safety officer: The ultimate long-term goal for us is to identify patients most at risk of harm from side-effects with a particular medicine due to their underlying genetic make-up, and avoid them suffering from that harm.”

As she announced MHRA’s move to personalised medicine, Dr. June Raine, the CEO of MHRA predicted: Almost a third of adverse reactions to medicines could be prevented with the introduction of genetic testing.”

Read More: Personalised medicine will make drug experimentation on populations the norm

The DreamBiBig

From our advertisers